Lung cancer remains one of the deadliest malignancies worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Advances in precision oncology have transformed treatment by tailoring therapies based on tumor-specific genetic alterations.
 

Molecular Testing & Targeted Therapy

Molecular testing, including next-generation sequencing (NGS), helps identify actionable mutations like EGFR, ALK, ROS1, BRAF, MET exon 14, and NTRK fusions, allowing oncologists to prescribe targeted therapies such as osimertinib (EGFR), alectinib (ALK), and crizotinib (ROS1). These therapies improve progression-free survival (PFS) while reducing chemotherapy-related toxicity.